R&D Incentives (Sec 35 with DSIR Registration)

DSIR — the Department of Scientific and Industrial Research — is a Government of India body under the Ministry of Science and Technology. For income-tax purposes, DSIR recognises the in-house R&D units of companies engaged in manufacture or production, which is a statutory pre-condition for those companies to claim the enhanced deduction framework under Section 35(2AB) of the Income-tax Act. Without DSIR recognition of the specific facility, a company cannot access the 35(2AB) route, though it may still claim research expenditure under the more general Section 35(1) provisions if the research is genuinely connected to its business.

Section 35(2AB), in its structure, is directed at companies engaged in the business of manufacture or production of an article or thing (subject to a specific negative list under the Eleventh Schedule). Pure services businesses, including most IT services companies, generally do not fall within this specific route in the way a manufacturing or production company does. That does not mean a services company cannot claim any research deduction — genuine scientific research expenditure connected to the business may still be considered under the more general Section 35(1) provisions — but the DSIR in-house R&D facility recognition route under 35(2AB) is structured around manufacture and production activity.

These are two distinct DSIR schemes. In-house R&D unit recognition, relevant to Section 35(2AB), is for companies engaged in manufacture or production that maintain their own dedicated research facility as part of their commercial operations. SIRO (Scientific and Industrial Research Organisation) recognition is a separate scheme aimed at research institutions, universities, and non-profit or dedicated R&D bodies whose primary purpose is conducting scientific research, often for external clients or in the public interest, and carries its own set of associated benefits including customs and GST concessions relevant to that category of organisation. A commercial manufacturing company seeking the Section 35(2AB) deduction should apply under the in-house R&D unit recognition scheme, not the SIRO scheme.

The rate of weighted deduction under the erstwhile Section 35(2AB) of the Income-tax Act, 1961 changed across successive Finance Acts. In earlier years the provision allowed a weighted deduction significantly above 100% of qualifying expenditure. Later Finance Acts progressively reduced this weighted rate, and from Assessment Year 2021-22 (Financial Year 2020-21) onwards, the deduction was 100% of the actual qualifying expenditure incurred — not a weighted or enhanced multiple. The 1961 Act has since been superseded by the Income Tax Act, 2025 (effective 1 April 2026), which restates this in-house R&D deduction under renumbered provisions while carrying forward the 100%-of-actual-expenditure position. Because the exact section reference and rate depend on the law in force for the assessment year being claimed, we always confirm both against the current statute at the time of computing and filing your claim, rather than relying on a 1961-Act citation or a figure quoted for a different year.

Broadly, expenditure incurred on the DSIR-approved in-house R&D facility qualifies — this typically includes revenue expenditure such as salaries of research personnel, cost of research materials and consumables, and contract research costs directly attributable to the recognised facility, as well as specified capital expenditure on the facility other than expenditure on land and, depending on the prevailing rules, certain categories of buildings. Expenditure that is not genuinely research-related — general production costs, routine quality control, or overheads not attributable to the R&D unit — does not qualify simply because it is incurred by a company that also has a recognised R&D facility.

There is no fixed statutory timeline that guarantees a specific processing period — DSIR's timeline depends on the completeness of the application, whether a facility visit or clarification round is required, and DSIR's current processing queue. Realistic planning should allow for the process to take several months from a well-prepared initial application, and longer where the application requires revision or where DSIR schedules a site inspection. We tell clients to plan the underlying business decision — including any related tax planning for the year — around a conservative timeline, not an optimistic best case.

Generally, the enhanced deduction under Section 35(2AB) is tied to the period for which the facility is recognised by DSIR and the prescribed-authority agreement is in effect. Expenditure incurred before recognition and the agreement are in place typically cannot be claimed under this specific provision for that earlier period, though it may in some cases be considered for a deduction under the more general Section 35(1) provisions if it independently qualifies as scientific research expenditure related to the business. This is a fact-specific question and we review the exact dates of recognition, the agreement, and the expenditure timeline for each client's situation before advising on what can be claimed for which period.

Form 3CK is the application form a company files with DSIR seeking recognition of its in-house R&D facility. Form 3CM is the recognition/approval certificate DSIR issues once it is satisfied the facility qualifies. Form 3CL is the annual report of quantified R&D expenditure that must be filed for each year the recognition remains active, which DSIR forwards to the Income-tax Department as supporting evidence for the deduction claimed in that year's tax return. In short: 3CK is the ask, 3CM is the approval, and 3CL is the recurring annual proof of ongoing qualifying expenditure.

A missed or inaccurate Form 3CL filing breaks the documented chain that the tax department relies on to verify a Section 35(2AB) claim for that year. This significantly increases the risk that the deduction claimed in the tax return for that year is questioned or disallowed at assessment, even where the underlying research expenditure was entirely genuine, simply because the statutory reporting evidence is missing or incomplete. It does not automatically mean recognition itself is cancelled, but it creates a real and avoidable risk for that specific year's claim.

DSIR recognition is separately relevant to certain customs duty concession schemes for scientific and research equipment imported by recognised R&D institutions, and to specified GST provisions applicable to research-related goods and institutions. The exact concessions available, the eligible categories of equipment, and the procedural requirements are governed by separate customs and GST notifications, and eligibility depends on the specific notification in force and the nature of the equipment being imported. We advise clients with DSIR recognition to explore these adjacent benefits as a distinct exercise once income-tax recognition is in place, rather than assuming automatic eligibility.

There is no minimum company size or age threshold under Section 35(2AB) itself — any company meeting the manufacture/production activity criteria and maintaining a genuine, DSIR-recognisable in-house R&D facility can apply, including a relatively young manufacturing or deep-tech hardware startup. In practice, DSIR does expect the facility, personnel, and research activity to be substantive enough to constitute genuine ongoing research, which means a very early-stage company with minimal R&D infrastructure may need to build up its facility and documentation before an application is realistic. We assess this readiness honestly rather than encouraging a premature application.

No, these are entirely different recognitions from different government bodies, serving different purposes. DPIIT (Department for Promotion of Industry and Internal Trade) Startup Recognition relates to eligibility for the Startup India scheme's benefits, including certain tax exemptions under Section 80-IAC and other startup-specific relief. DSIR recognition relates specifically to recognition of an in-house R&D facility for the purposes of Section 35(2AB) research expenditure deductions. A company can hold one, both, or neither — they are independent processes with independent eligibility criteria, and holding DPIIT recognition does not automatically confer DSIR recognition or vice versa.

DSIR recognition is typically granted with reference to specific, identified R&D facility locations described in the Form 3CK application. A company with R&D activity spread across multiple sites should disclose all relevant locations in its application, supported by facility-specific documentation for each site, rather than applying for recognition of one site while conducting unrecognised research at others. Expenditure at a location not covered by the recognition may not be eligible for the Section 35(2AB) claim for that location.

Where R&D personnel split time between research and other functions such as production support or quality control, the qualifying expenditure should reflect only the portion of their cost genuinely attributable to R&D activity, supported by time allocation records, project logs, or a reasonable and consistently applied allocation methodology. Claiming the full cost of a partially-allocated employee as pure R&D expenditure without a defensible basis for the allocation is a common point of scrutiny.

The Eleventh Schedule to the Income-tax Act lists specified articles or things whose manufacture or production is excluded from certain tax benefits, including relevance to Section 35(2AB) eligibility. A company engaged in manufacturing an item that falls within this negative list may not be eligible for the Section 35(2AB) in-house R&D deduction route even if it otherwise maintains a genuine research facility, though it may still access the general Section 35(1) provisions. We check the Eleventh Schedule against the company's specific manufactured products at the very start of the eligibility assessment, since this is a threshold question that determines whether the DSIR 35(2AB) pathway is available at all.

Capital expenditure claimed under the scientific research provisions is, subject to the applicable conditions in the Income-tax Act, generally treated similarly to unabsorbed depreciation for carry-forward purposes where the deduction cannot be fully absorbed against the income of the relevant year. The precise mechanics depend on the specific sub-section under which the capital expenditure is claimed and the company's overall tax computation for the year, and should be reviewed as part of the annual tax filing rather than assumed to work identically to ordinary business loss carry-forward.

PNPC structures this as two components discussed and agreed upfront: a fixed fee for the DSIR recognition process itself (eligibility assessment, Form 3CK preparation, application support through to Form 3CM recognition), and a separate ongoing annual fee for maintaining compliance — Form 3CL filing, tax return claim computation, and renewal support — since DSIR recognition, once obtained, requires active annual maintenance to keep the benefit alive. We provide a written scope and fee letter before any work begins, so there is no ambiguity about what the one-time application fee covers versus the ongoing annual compliance engagement.

Where DSIR schedules a facility visit as part of its evaluation, officials typically assess whether the physical infrastructure, equipment, and ongoing projects described in the Form 3CK application match what actually exists at the facility, and may ask research personnel questions about ongoing work. Companies that submit an application describing a facility or activity level that does not match reality on inspection risk both rejection of that application and difficulty with future applications. We prepare clients for this visit — briefing relevant personnel, ensuring the facility is presentable and matches the application narrative, and anticipating likely questions.

Yes. DSIR recognition is not permanent or unconditional — it is typically granted for a defined validity period requiring renewal, and DSIR retains the ability to review or withdraw recognition where the facility ceases to meet the criteria on which it was granted, where reporting obligations are not met, or where the company's activity materially changes. Maintaining recognition requires ongoing substantive R&D activity at the facility, not just the historical fact of having once been recognised.

A company that has opted for the concessional corporate tax rate under Section 115BAA generally forgoes certain specified deductions and incentives as a condition of that concessional rate, and the interaction between 115BAA and Section 35(2AB) needs to be checked against the specific list of deductions restricted under 115BAA for the relevant assessment year, since tax provisions in this area have been subject to periodic clarification. This is exactly the kind of interaction question that should be reviewed at the company's overall tax-planning level — the R&D deduction should not be pursued in isolation without checking how it fits with the company's broader tax regime election.

Yes. Where a UAE-headquartered group has an Indian manufacturing subsidiary undertaking genuine in-house R&D, the DSIR recognition and Section 35(2AB) process applies to the Indian entity under Indian tax law in the same way as for a purely domestic company. PNPC's Dubai office coordinates with our India teams so that the UAE parent's reporting, transfer pricing considerations for any intercompany R&D cost arrangements, and the Indian subsidiary's DSIR and Section 35 compliance are handled coherently under one engagement rather than being split across disconnected advisors in each jurisdiction.

Any claim involving a specialised deduction with government-body recognition and material financial value can attract closer review as part of the normal assessment process, simply because of the deduction's materiality and the historical pattern of disputes in this area across industries. This is not a reason to avoid a legitimate claim, but it is a reason to maintain complete, contemporaneous documentation from the outset — DSIR recognition, the prescribed-authority agreement, annual Form 3CL filings, and underlying project and expenditure records — so that if the claim is examined, the response is straightforward.

A weighted deduction allows a taxpayer to deduct an amount greater than 100% of the actual expenditure incurred — for example, historically, Section 35(2AB) at various points in its legislative history allowed deductions well above the actual rupee amount spent, as a policy incentive to encourage private-sector R&D investment. Successive Finance Acts progressively reduced this weighting, and the enhanced weighted-deduction era for Section 35(2AB) has ended — the applicable rate from Assessment Year 2021-22 onwards is 100% of actual qualifying expenditure. References to 200% or 150% that still circulate refer to earlier assessment years and should not be relied upon for current-year tax planning without checking the rate actually in force for the year being claimed.

Yes, a company can generally reapply after addressing the specific gaps that led to the initial rejection or query — whether that is facility infrastructure, personnel documentation, project descriptions, or expenditure records. A rejection is not necessarily permanent, but reapplying without genuinely addressing the underlying deficiency tends to produce the same outcome. We review the reasons for any prior rejection carefully before advising a client to reapply, and where the gap is substantive (for example, insufficient facility investment), we advise building up the facility over a defined period before a second attempt rather than reapplying prematurely.

DSIR recognition and the Section 35(2AB) deduction apply at the level of the specific company that owns and operates the recognised R&D facility and incurs the qualifying expenditure — recognition is not automatically shared across a group merely because a parent or another group company holds it. A subsidiary conducting genuine, substantive in-house R&D as part of its own manufacture/production business can apply for its own DSIR recognition in its own right, subject to meeting the eligibility criteria independently.

Many generic advisors treat DSIR recognition as a one-time filing exercise and stop engaging once Form 3CM is received. PNPC treats the Section 35(2AB) benefit as a multi-year compliance relationship: we assess eligibility honestly before applying, prepare the technical and financial documentation to DSIR's actual evidentiary expectations, and then stay engaged for the annual Form 3CL filing, the tax return claim computation, renewal tracking, and scrutiny support that keep the benefit alive and defensible year after year. A one-time filing service that disappears after recognition leaves the client exposed exactly when the annual reporting discipline matters most.

There is no single, universally published minimum rupee threshold — DSIR's evaluation is based on the substance and credibility of the R&D facility, personnel, and ongoing projects rather than a fixed spend number alone, though in practice a facility with very minimal investment and activity is unlikely to be viewed as a genuine, substantive R&D operation. We assess a prospective applicant's facility and spend profile against DSIR's practical expectations during the initial consultation and advise honestly if the current scale is unlikely to support a successful application yet.

We help with both. The DSIR application and Section 35 tax claim are only as strong as the underlying cost-accounting system that tracks and segregates R&D expenditure on an ongoing basis. As part of this engagement, we review or help set up a cost-centre structure for R&D — separating R&D salaries, consumables, and capital expenditure from general business costs — so that the numbers reported to DSIR in Form 3CL and claimed in the tax return are drawn directly from a defensible internal system, not reconstructed retrospectively each year.

Claiming the Section 35(2AB) deduction without valid DSIR recognition of the specific facility and without the executed prescribed-authority agreement is a claim made without satisfying the statutory pre-conditions of the provision, and is highly likely to be disallowed on assessment or scrutiny, potentially along with interest and, depending on the facts, penalty exposure for an incorrect claim. This is different from a mere documentation gap on an otherwise valid claim — it is a claim under a provision whose basic eligibility conditions were never met.

Because DSIR's procedural requirements and the Income-tax Act's Section 35 provisions are both subject to periodic administrative and legislative change, we review the applicable rules each year as part of preparing the annual Form 3CL filing and tax return claim — rather than relying on the rules as they stood at the time recognition was originally granted. Where a Finance Act amendment or DSIR circular materially affects an active client's claim, we proactively flag it as part of our annual compliance engagement.

No professional advisor can or should guarantee a government body's discretionary approval decision, and we do not make that promise. What we do commit to is a thorough, honest eligibility assessment before applying, a well-prepared application built to DSIR's actual evidentiary expectations, and full support through queries, clarifications, and any facility visit. Where we believe a facility or company is not yet ready for a successful application, we say so upfront rather than taking on the engagement and hoping for the best outcome.

Companies should retain the DSIR Form 3CM recognition certificate, the executed prescribed-authority agreement, every year's Form 3CL filing, the underlying project and personnel documentation, and the detailed expenditure records supporting each year's claim, generally for the full period the Income-tax Act allows for reopening or scrutiny of that assessment year, which can extend well beyond the year the return was originally filed. We recommend treating this as part of the company's permanent statutory record set, not routine paperwork to be discarded after a few years.